{"id":"NCT00993473","sponsor":"Sanofi","briefTitle":"6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes","officialTitle":"A 24-week, Randomized, Open-label, Parallel Group Multinational Comparison of Lantus速 (Insulin Glargine) Given in the Morning as Once-a-day Basal Insulin Versus Neutral Protamine Hagedorn (NPH) Insulin, in Children With Type 1 Diabetes Mellitus Aged at Least 1 Year to Less Than 6 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2009-10-12","resultsPosted":"2012-06-22","lastUpdate":"2012-06-27"},"enrollment":125,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Insulin glargine (HOE901)","otherNames":["Lantus速"]},{"type":"DRUG","name":"Neutral Protamine Hagedorn (NPH) insulin","otherNames":[]},{"type":"DRUG","name":"Insulin lispro","otherNames":["Humalog速"]}],"arms":[{"label":"Lantus (insulin glargine)","type":"EXPERIMENTAL"},{"label":"NPH insulin","type":"ACTIVE_COMPARATOR"}],"summary":"The primary study objective was to compare the rate of \"all hypoglycemia\" (composite outcome of the following hypoglycemia events: symptomatic hypoglycemia episodes, low continuous glucose monitoring system (CGMS) excursions confirmed by fingerstick blood glucose (FSBG), low FSBG readings performed at other times) between children treated with Lantus (insulin glargine) and Neutral Protamine Hagedorn (NPH) insulin.\n\nSecondary objectives were to compare insulin glargine and NPH in terms of:\n\n* rates of specific types of hypoglycemia: symptomatic, severe, nocturnal, nocturnal symptomatic, and severe nocturnal symptomatic hypoglycemia\n* HbA1c change from baseline to end-of-treatment, and HbA1c at end-of-treatment\n* percentage of patients reaching HbA1c less than 7.5% (target value) at end of treatment\n* average blood glucose over whole trial and at end of trial, as estimated by continuous glucose monitoring (CGM), and blood glucose variability","primaryOutcome":{"measure":"Event Rate of \"All Hypoglycemia\" Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)","timeFrame":"6 months","effectByArm":[{"arm":"Lantus (Insulin Glargine)","deltaMin":192.75,"sd":119.28},{"arm":"NPH Insulin","deltaMin":168.91,"sd":101.04}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":15},"locations":{"siteCount":61,"countries":["United States","Austria","Brazil","Chile","Czechia","Germany","Hungary","India","Mexico","Peru","Poland","Romania","Russia","South Africa","Spain","Turkey (T端rkiye)"]},"refs":{"pmids":["25041275"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":62},"commonTop":["Gastroenteritis","Nasopharyngitis","Upper respiratory tract infection","Pyrexia","Vomiting"]}}